Neurotrope’s Bryostatin Appears to Improve Cognition in Patients with Moderate to Severe Alzheimer’s

Neurotrope’s Bryostatin Appears to Improve Cognition in Patients with Moderate to Severe Alzheimer’s
Neurotrope‘s investigational drug bryostatin might improve cognition and the ability of patients with moderate to severe Alzheimer’s disease to care for themselves, according to a Phase 2 trial. The placebo-controlled trial (NCT02431468) evaluated the safety, tolerability, and effectiveness of bryostatin in 147 people with Alzheimer’s disease (AD). Patients underwent a 12-week treatment with two dose levels of

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *